medicationControlledSchedule II (US)Prescription only (US)Approved by the FDA (Focalin, Focalin XR) as the d-enantiomer of methylphenidate for ADHDFederally controlled as a Schedule II stimulant in the United States due to abuse and dependence potential
DexmethylphenidateBenefits, Dosage & Interactions
Also known as: Focalin
Dexmethylphenidate, often known by its brand name Focalin, is a central nervous system (CNS) stimulant medication. It is primarily prescribed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults. It is typically taken in the morning. The reported plasma half-life is about 2.2 hours, which shapes dosing frequency.
How much Dexmethylphenidate do people take?
Pediatric ADHD trials titrated dexmethylphenidate from about 2.5 mg up to 20 mg/day; fatigue trials in cancer and sarcoidosis patients used doses in a similar 5–20 mg/day range. Route reported: Oral tablet or capsule. Frequency reported: Twice daily for immediate-release ADHD dosing in the cited pediatric trial; once daily for the extended-release capsule study and the fatigue trials. These are amounts documented in the cited studies and labels for Dexmethylphenidate — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 4 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
4 human randomized trials and regulatory approval on file.
Plasma half-life
~2.2 h
Typical timing
in the morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Pediatric ADHD trials titrated dexmethylphenidate from about 2.5 mg up to 20 mg/day; fatigue trials in cancer and sarcoidosis patients used doses in a similar 5–20 mg/day range[1][2][3][4]
- Frequency
- Twice daily for immediate-release ADHD dosing in the cited pediatric trial; once daily for the extended-release capsule study and the fatigue trials[1][2][3][4]
Reported for Dexmethylphenidate in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Dexmethylphenidate entry is written from. Each number matches an inline marker above.
- [1]A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorderWigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD · Journal of the American Academy of Child and Adolescent Psychiatry · 2004 · Peer-reviewed · PMID 15502600
- [2]Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trialLower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z · Journal of Pain and Symptom Management · 2009 · Peer-reviewed · PMID 19896571
- [3]Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigueLower EE, Harman S, Baughman RP · Chest · 2008 · Peer-reviewed · PMID 18263672
- [4]A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity DisorderKollins SH, Braeckman R, Guenther S, Barrett AC, Mickle TC, Oh C · Journal of Child and Adolescent Psychopharmacology · 2021 · Peer-reviewed · PMID 34714120
References & Evidence
Sources on this page that document Dexmethylphenidate dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Dexmethylphenidate?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Dexmethylphenidate, often known by its brand name Focalin, is a central nervous system (CNS) stimulant medication. It is primarily prescribed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults. It is the d-threo-isomer of methylphenidate, meaning it is one of the two mirror-image molecules (enantiomers) that make up racemic methylphenidate. Dexmethylphenidate is considered the more pharmacologically active component of methylphenidate. It is available in immediate-release and extended-release formulations. As a controlled substance, its use is regulated due to its potential for abuse and dependence. (FDA label, DrugBank)
What does the research say about Dexmethylphenidate?
Tap a section to expand.
Dexmethylphenidate exerts its therapeutic effects by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine. It does this by blocking the reuptake of these neurotransmitters into the presynaptic neuron. Essentially, it prevents dopamine and norepinephrine from being reabsorbed too quickly, leaving more of them available in the synaptic cleft to bind to receptors on the postsynaptic neuron. This enhanced neurotransmission in specific brain regions, particularly those involved in attention and impulse control (like the prefrontal cortex), is thought to lead to improved focus, reduced impulsivity, and decreased hyperactivity in individuals with ADHD. The precise mechanism by which these changes in neurotransmitter levels alleviate ADHD symptoms is still an area of ongoing research, but it is well-established that CNS stimulants like dexmethylphenidate have a beneficial effect. (FDA label, DrugBank, PubChem)
Source for this section: Sources for How does Dexmethylphenidate work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of dexmethylphenidate is the symptomatic improvement for individuals diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). For those with ADHD, therapy with dexmethylphenidate can lead to:
* **Improved attention and focus:** Patients often report an enhanced ability to concentrate on tasks and sustain attention.
* **Reduced impulsivity:** The medication can help lessen impulsive behaviors and decisions.
* **Decreased hyperactivity:** Motor restlessness and excessive activity levels can be diminished.
* **Better organizational skills:** Some individuals experience improvements in planning and task completion.
* **Enhanced academic and occupational performance:** By mitigating core ADHD symptoms, individuals may perform better in school or work settings.
These benefits contribute to improved daily functioning and quality of life for many individuals with ADHD. (FDA label, MedlinePlus)
Multiple clinical studies have demonstrated the efficacy of dexmethylphenidate in treating ADHD. For instance, a randomized, double-blind, placebo-controlled study published in the *Journal of the American Academy of Child and Adolescent Psychiatry* (source type: peer-reviewed research journal, example) found that extended-release dexmethylphenidate significantly improved ADHD symptoms in children and adolescents compared to placebo. A review of stimulant medications for ADHD, often citing data from numerous controlled trials, consistently shows that these medications, including dexmethylphenidate, are effective in reducing the core symptoms of ADHD across various age groups. The FDA approval of dexmethylphenidate for ADHD was based on evidence from these controlled clinical trials demonstrating its safety and efficacy. (FDA label, MedlinePlus)
As a CNS stimulant, dexmethylphenidate can cause various side effects. Common side effects often include:
* Loss of appetite
* Insomnia (difficulty sleeping)
* Nausea, stomach pain
* Headache
* Anxiety or nervousness
* Irritability
* Increases in blood pressure and heart rate (usually mild)
Less common but more serious side effects can include:
* Cardiac problems: serious cardiovascular events such as sudden death in patients with structural cardiac abnormalities or other serious heart problems.
* Psychiatric problems: new or worsening psychotic or manic symptoms in children and adolescents.
* Growth suppression: a slight slowing in growth rate and weight gain in children.
* Circulation problems: peripheral vasculopathy, including Raynaud's phenomenon.
* Priapism (a prolonged and painful erection).
Patients should report any concerning side effects to their prescribing clinician immediately. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Dexmethylphenidate?: Jumps to this entry in the sources and references list at the end of the page.
Dexmethylphenidate carries several important warnings. It is a Schedule II controlled substance, indicating a high potential for abuse and dependence. Misuse can lead to addiction, overdose, and even death. Patients should be carefully monitored for signs of abuse and diversion. Cardiovascular considerations are paramount; patients with pre-existing serious heart problems, congenital heart defects, or severe hypertension should generally not use this medication without careful cardiac evaluation, as stimulants can increase heart rate and blood pressure. There is a risk of sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Psychiatric issues are also a concern; stimulant medications can exacerbate pre-existing psychotic disorders and should be used with extreme caution in patients with a history of psychosis or bipolar disorder. New psychotic or manic symptoms can emerge during treatment. Growth suppression has been observed in children treated with stimulants, and growth should be monitored. Visual disturbances like blurred vision have been reported. Rare but serious side effects like priapism have also occurred. All patients should be screened for cardiac health prior to starting this medication. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Dexmethylphenidate?: Jumps to this entry in the sources and references list at the end of the page.
Dexmethylphenidate is contraindicated in certain situations due to potential risks. It should not be used in individuals with:
* **Known hypersensitivity:** Patients with an allergy to methylphenidate or other components of the medication.
* **Significant anxiety, tension, or agitation:** The stimulant effect can worsen these conditions.
* **Glaucoma:** Could increase intraocular pressure.
* **Motor tics, Tourette's syndrome, or a family history of Tourette's syndrome:** Stimulants can exacerbate tics.
* **During or within 14 days following the administration of monoamine oxidase inhibitors (MAOIs):** Concurrent use can cause a hypertensive crisis.
* **Severe hypertension or severe cardiovascular disease:** Due to the potential for increased blood pressure and heart rate.
* **Hyperthyroidism:** Can worsen symptoms.
Always ensure that a patient's full medical history is reviewed by a licensed clinician before prescribing this medication. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Dexmethylphenidate not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Dexmethylphenidate should not be mixed with certain medications due to the risk of serious adverse reactions. Key interactions include:
* **Monoamine Oxidase Inhibitors (MAOIs):** Concurrent use, or use within 14 days of discontinuing an MAOI, can lead to a hypertensive crisis (a sudden and dangerous increase in blood pressure). This interaction is severe and potentially life-threatening.
* **Vasopressor Agents:** Dexmethylphenidate may potentiate the pressor effect of vasopressor agents, increasing blood pressure excessively. Close monitoring is required.
* **Halogenated Anesthetics:** There is a risk of sudden blood pressure and heart rate increases during surgery if dexmethylphenidate is used concomitantly with halogenated anesthetics. Discontinuation of dexmethylphenidate on the day of surgery might be considered.
* **Antihypertensive Drugs:** Dexmethylphenidate can diminish the effectiveness of drugs used to treat high blood pressure, necessitating a possible adjustment in dosage of antihypertensives.
* **Coumarin Anticoagulants (e.g., Warfarin):** Dexmethylphenidate may inhibit the metabolism of these drugs, potentially increasing their anticoagulant effect and risk of bleeding. Close monitoring of INR and prothrombin time is recommended.
* **Anticonvulsants (e.g., Phenobarbital, Phenytoin, Primidone):** Dexmethylphenidate may inhibit the metabolism of certain anticonvulsants, leading to increased plasma concentrations and potential toxicity. Dosage adjustments may be necessary.
* **Tricyclic Antidepressants (TCAs) (e.g., Imipramine, Desipramine):** Dexmethylphenidate may inhibit the metabolism of TCAs, potentially increasing their plasma concentrations and risk of adverse effects.
Patients should always inform their clinician and pharmacist about all medications, supplements, and herbal products they are taking. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Dexmethylphenidate?: Jumps to this entry in the sources and references list at the end of the page.
Dexmethylphenidate is typically taken in the morning. The specific timing and frequency depend on whether an immediate-release (IR) or extended-release (ER) formulation is used. Immediate-release formulations are usually taken two or three times a day, with the first dose in the morning and subsequent doses during the day, often separated by about 4 hours. Extended-release formulations are designed to be taken once daily in the morning, as they slowly release the medication over several hours. The exact number of doses and timing throughout the day must be directed by a licensed clinician. It can be taken with or without food. (FDA label, MedlinePlus)
Source for this section: Sources for When should you take Dexmethylphenidate?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Dexmethylphenidate is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Dexmethylphenidate?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed source; confirm with your provider. |
| Phenelzine | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. |
| Tranylcypromine | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. |
| Selegiline | Avoid | Compound pairConfidence: theoretical | MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. |
Frequently asked questions about Dexmethylphenidate
Dexmethylphenidate (Focalin) is the more active d-isomer of methylphenidate. Methylphenidate is a racemic mixture containing both d- and l-isomers, but the d-isomer is responsible for most of its therapeutic effects. Therefore, dexmethylphenidate is often prescribed in lower doses to achieve similar effects as methylphenidate. (DrugBank)
For immediate-release formulations, effects can typically be noticed within 30 to 60 minutes after taking a dose. Extended-release formulations also begin to work relatively quickly but provide a sustained effect over several hours. (FDA label)
Yes, dexmethylphenidate is a Schedule II controlled substance, meaning it has a high potential for abuse and dependence. Misuse can lead to addiction. It should only be used under strict medical supervision and as prescribed. (FDA label)
Studies have shown that stimulant medications like dexmethylphenidate can cause a slight slowing in growth rate and weight gain in children. Children on this medication should have their height and weight monitored regularly by their clinician. (FDA label)
If you miss a dose, take it as soon as you remember that day, unless it is close to evening or your next scheduled dose. Taking it too late in the day can cause insomnia. Never double up on doses. Always follow your prescribing clinician's specific instructions regarding missed doses. (MedlinePlus)
Interaction risk for Dexmethylphenidate comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Dexmethylphenidate is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 2.2 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Dexmethylphenidate with no sign-up.
There is no single answer for Dexmethylphenidate plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Dexmethylphenidate with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 2.2 hours is why protocols often split Dexmethylphenidate across the day rather than using a single dose. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
For Dexmethylphenidate the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Pediatric ADHD trials titrated dexmethylphenidate from about 2.5 mg up to 20 mg/day; fatigue trials in cancer and sarcoidosis patients used doses in a similar 5–20 mg/day range. Route reported: Oral tablet or capsule. Frequency reported: Twice daily for immediate-release ADHD dosing in the cited pediatric trial; once daily for the extended-release capsule study and the fatigue trials. These are amounts documented in the cited studies and labels for Dexmethylphenidate — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Dexmethylphenidate?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Dexmethylphenidate(opens PubMed in a new tab)Drugs · 2002 · PMID 12215063 · https://pubmed.ncbi.nlm.nih.gov/12215063/
- 2.Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride(opens PubMed in a new tab)Drugs R D · 2002 · PMID 12455205 · https://pubmed.ncbi.nlm.nih.gov/12455205/
- 3.Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder(opens PubMed in a new tab)Am J Health Syst Pharm · 2014 · PMID 24973373 · https://pubmed.ncbi.nlm.nih.gov/24973373/
- 4.Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder(opens PubMed in a new tab)CNS Drugs · 2009 · PMID 19958043 · https://pubmed.ncbi.nlm.nih.gov/19958043/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a603014.html
- PubChem CID 154100(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/154100
Verify at
Publisher search links for Dexmethylphenidate. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Dexmethylphenidate?
Plain-text summary, safe to quote verbatim:
Dexmethylphenidate, often known by its brand name Focalin, is a central nervous system (CNS) stimulant medication. It is primarily prescribed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults. It is typically taken in the morning. The reported plasma half-life is about 2.2 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/dexmethylphenidate
Dexmethylphenidate cheat sheet
DoseRoutine cheat sheet · Medication
Dexmethylphenidate
Dexmethylphenidate, often known by its brand name Focalin, is a central nervous system (CNS) stimulant medication. It is primarily prescribed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults.
Evidence
Strong
4 human randomized trials and regulatory approval on file.
Studied range
Pediatric ADHD trials titrated dexmethylphenidate from about 2.5 mg up to 20 mg/day; fatigue trials in cancer and sarcoidosis patients used doses in a similar 5–20 mg/day range
Route
Oral tablet or capsule
Frequency studied
Twice daily for immediate-release ADHD dosing in the cited pediatric trial; once daily for the extended-release capsule study and the fatigue trials
Half-life
~2.2 h
Timing
in the morning
Schedule II (US)Prescription only (US)Approved by the FDA (Focalin, Focalin XR) as the d-enantiomer of methylphenidate for ADHDFederally controlled as a Schedule II stimulant in the United States due to abuse and dependence potential
Key references
- A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder (2004)
- Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial (2009)
- Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue (2008)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/dexmethylphenidate
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Dexmethylphenidate — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/dexmethylphenidate
What compounds are similar to Dexmethylphenidate?
Others in the medication category or studied for the same goals.